FDA Clarifies Skin Protectant Labeling, Ingredient Combination Options
This article was originally published in The Rose Sheet
Executive SummaryFDA endeavors to clarify the active ingredients manufacturers may combine in OTC skin protectant drug products and corresponding label requirements in draft guidance released Aug. 1
You may also be interested in...
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.